| Literature DB >> 33657418 |
Silvia Marchiano1, Tien-Ying Hsiang2, Akshita Khanna1, Ty Higashi3, Leanne S Whitmore2, Johannes Bargehr4, Hongorzul Davaapil4, Jean Chang2, Elise Smith2, Lay Ping Ong4, Maria Colzani4, Hans Reinecke1, Xiulan Yang1, Lil Pabon5, Sanjay Sinha4, Behzad Najafian6, Nathan J Sniadecki7, Alessandro Bertero1, Michael Gale8, Charles E Murry9.
Abstract
COVID-19 patients often develop severe cardiovascular complications, but it remains unclear if these are caused directly by viral infection or are secondary to a systemic response. Here, we examine the cardiac tropism of SARS-CoV-2 in human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and smooth muscle cells (hPSC-SMCs). We find that that SARS-CoV-2 selectively infects hPSC-CMs through the viral receptor ACE2, whereas in hPSC-SMCs there is minimal viral entry or replication. After entry into cardiomyocytes, SARS-CoV-2 is assembled in lysosome-like vesicles and egresses via bulk exocytosis. The viral transcripts become a large fraction of cellular mRNA while host gene expression shifts from oxidative to glycolytic metabolism and upregulates chromatin modification and RNA splicing pathways. Most importantly, viral infection of hPSC-CMs progressively impairs both their electrophysiological and contractile function, and causes widespread cell death. These data support the hypothesis that COVID-19-related cardiac symptoms can result from a direct cardiotoxic effect of SARS-CoV-2.Entities:
Keywords: COVID-19; SARS-CoV-2; arrhythmias and heart failure; cardiac infection; cardiovascular disease; hESC-CMs; hPSC-CMs; human pluripotent stem cell-derived cardiomyocytes; viral myocarditis
Mesh:
Substances:
Year: 2021 PMID: 33657418 PMCID: PMC7881699 DOI: 10.1016/j.stemcr.2021.02.008
Source DB: PubMed Journal: Stem Cell Reports ISSN: 2213-6711 Impact factor: 7.765